Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir

Journal of Virology

Volumn 71, Issue 5, 1997, Pages 3872-3878

  Sasadeusz, Joseph J ^a,c   Tufaro, Frank ^a   Safrin, Sharon ^b,d   Schubert, Kathryn ^a   Hubinette, Maria M ^a   Cheung, Peter K ^a   Sacks, Stephen L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Viridae Clinical Sciences Inc   (Canada)

^d GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; THYMIDINE KINASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; ENZYME DEFICIENCY; FRAMESHIFT MUTATION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 0030901540     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.5.3872-3878.1997     Document Type: Article

References (50)

1. Baumann, B., M. J. Potash, and G. Kohler. 1985. Consequences of frameshift mutations at the immunoglobulin heavy chain locus of the mouse. EMBO J. 4:351-359.
2. Birch, C. J., G. Tachedjian, R. R. Doherty, K. Hayes, and I. D. Gust. 1990. Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. J. Infect. Dis. 162: 731-734.
3. Breinig, M. K., L. A. Kingsley, J. A. Armstrong, D. J. Freeman, and M. Ho. 1990. Epidemiology of genital herpes in Pittsburgh: serologic, sexual, and racial correlates of apparent and inapparent herpes simplex infection. J. Infect. Dis. 162:299-305.
4. Burns, W. H., R. Saral, G. W. Santos, O. L. Laskin, and P. S. Lietman. 1982. Isolation and characterization of resistant herpes simplex virus after acyclovir therapy. Lancet i:421-423.
5. Chatis, P. A., and C. S. Crumpacker. 1991. Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses. Virology 180:793-797.
6. Coen, D. M., M. Kosz-Vnenchak, J. G. Jacobson, D. A. Leib, C. L. Bogard, P. A. Schaffer, K. L. Tyler, and D. M. Knipe. 1989. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc. Natl. Acad. Sci. USA 86:4736-4740.
7. Collins, P., B. A. Larder, N. M. Oliver, S. Kemp, I. W. Smith, and G. Darby. 1989. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. J. Gen. Virol. 70:375-382.
8. Crumpacker, C. S., L. E. Schnipper, S. I. Marlowe, P. N. Kowalsky, B. J. Hershey, and M. J. Levin. 1982. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N. Engl. J. Med. 306:343-346.
9. Darby, G., and H. J. Field. 1981. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature 289:81-83.
10. Darby, G., B. Larder, and M. M. Inglis. 1986. Evidence that the 'active centre' of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide. J. Gen. Virol. 67:753-758.
11. Efsthaniou, S., S. Kemp, G. Darby, and A. C. Minson. 1989. The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. J. Gen. Virol. 70:869-879.
12. Ellis, M. N., P. M. Keller, J. A. Fyfe, J. L. Martin, J. F. Rooney, S. E. Straus, S. N. Lehrman, and D. W. Barry. 1987. Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity. Antimicrob. Agents Chemother. 31:1117-1125.
13. Englund, J. A., M. E. Zimmerman, E. M. Swierkosz, J. L. Goodman, D. R. Scholl, and H. H. Balfour, Jr. 1990. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann. Intern. Med. 112:416-422.
14. Erlich, K. S., J. Mills, P. Chatis, G. J. Mertz, D. F. Busch, S. E. Follansbee, R. M. Grant, and C. S. Crumpacker. 1989. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 320:293-296.
15. Farabaugh, P. J., U. Schmeissner, M. Hofer, and J. H. Miller. 1978. Genetic studies of the lac represser. VII. On the molecular nature of spontaneous hotspots on the lacI gene of Escherichia coli. J. Mol. Biol. 126:847-863.
16. Hill, E. L., G. A. Hunter, and M. N. Ellis. 1991. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 35:2322-2328.
17. Horsburgh, B. C., H. Kollums, H. Hauser, and D. Coen. 1996. Translational recoding induced by G-rich mRNA sequences that form unusual structures. Cell 86:949-959.
18. Hwang, C. B. C., and H. J. H. Chen. 1995. An altered spectrum of herpes simplex virus mutations mediated by an antimutator DNA polymerase. Gene 152:191-193.
19. Hwang, C. B. C., B. Horsburgh, E. Pelosi, S. Roberts, P. Digard, and D. Coen. 1994. A net +1 frameshift permits synthesis of thymidine kinase from a drug-resistant herpes simplex virus mutant. Proc. Natl. Acad. Sci. USA 91:5461-5465.
20. Johnson, R. E., A. J. Nahmias, L. S. Magder, F. K. Lee, C. A. Brooks, and C. B. Snowden. 1990. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N. Engl. J. Med. 32:7-12.
21. Kit, S., M. Kit, H. Qavi, D. Trkula, and H. Otsuka. 1983. Nucleotide sequence of the herpes simplex type 2 (HSV-2) thymidine kinase gene and predicted amino acid sequence of thymidine kinase polypeptide and its comparison with the HSV-1 thymidine kinase gene. Biochim. Biophys. Acta 741:158-170.
22. Kit, S., M. Sheppard, H. Ichimura, S. Nusinoff-Lehrman, M. N. Ellis, J. A. Fyfe, and H. Otsuka. 1987. Nucleotide sequence changes in thymidine kinase gene of herpes simplex virus type 2 clones from an isolate of a patient treated with acyclovir. Antimicrob. Agents Chemother. 31:1483-1490.
23. Kost, R. G., E. L. Hill, M. Tigges, and S. E. Straus. 1993. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N. Engl. J. Med. 329:1777-1782.
24. Martin, J. L., M. N. Ellis, P. M. Keller, K. K. Biron, S. N. Lehrman, D. W. Barry, and P. A. Furman. 1985. Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates. Antimicrob. Agents Chemother. 28:181-187.
25. Mori, H., K. Shiraki, T. Kato, Y. Hayakawa, K. Yamanishi, and M. Takahashi. 1988. Molecular analysis of the thymidine kinase gene of thymidine kinase-deficient mutants of varicella-zoster virus. Intervirology 29:301-310.
26. Nahmias, A. J., F. K. Lee, and S. Beckman-Nahmias. 1990. Sero-epidemiological and serological patterns of herpes simplex virus infection in the world. Scand. J. Infect. Dis. Suppl. 69:19-36.
27. O'Brien, J. J., and D. M. Campoli-Richard. 1989. Acyclovir: an updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 37:233-309.
28. Okada, Y., G. Streisinger, J. Owen, J. Newton, A. Tsugita, and M. Inouye. 1972. Molecular basis of a mutational hot spot in the lysozyme gene of bacteriophaee T4. Nature 236:338-341.
29. Palu, G., G. Gerna, F. Bevilacqua, and A. Marcello. 1992. A point mutation in the thymidine kinase gene is responsible for acyclovir-resistance in herpes simplex virus type 2 sequential isolates. Virus Res. 25:133-144.
30. Parker, A. C., J. I. Craig, P. Collins, N. Oliver, and I. Smith. 1987. Acyclovir-resistant herpes simplex virus infection due to altered DNA polymerase. Lancet ii:1461.
31. Pinbrow, D., C. Sigurdson, L. Gold, B. A. Singer, C. Napoli, J. Brosius, T. J. Dull, and H. F. Noller. 1981. rII cistrons of bacteriophage T4 DNA sequence around the intercistronic divide and positions of genetic landmarks. J. Mol. Biol. 149:337-376.
32. Rechtin, T. M., M. E. Black, F. Mao, M. L. Lewis, and R. R. Drake. 1995. Purification and photoaffinity labeling of herpes simplex virus type 1 thymidine kinase. J. Biol. Chem. 270:7055-7060.
33. Sacks, S. L. 1988. Treatment of herpes genitalis, p. 87-114. In E. De Clercq (ed.), Clinical use of antiviral drugs. Martinus Nijhoff Publishing, Boston, Mass.
34. Sacks, S. L., R. Fox, P. Levendusky, H. G. Stiver, S. Roland, S. Nusinoff-Lehrman, and R. Keeney. 1988. Chronic suppression for six months compared with intermittent lesional therapy of frequently recurrent genital herpes using oral acyclovir: effects on lesions and nonlesional prodromes. Sex. Transm. Dis. 15:58-62.
35. Sacks, S. L., and B. A. Rennie. 1991. Clinical resistance to acyclovir (ACV) in herpes simplex virus type 2 (HSV-2) infection in AIDS: false in vitro susceptibility associated with viral heterogeneity (VHET), abstr. 1223, p. 303. In Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
36. Sacks, S. L., R. J. Wanklin, D. E. Reece, K. A. Hicks, K. L. Tyler, and D. M. Coen. 1989. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? Ann. Intern. Med. 111:893-899.
37. Safrin, S., C. Crumpacker, P. Chatis, R. Davis, R. Hafner, J. Rush, H. A. Kessler, B. Landry, J. Mills, and Other Members of the AIDS Clinical Trials Group. 1991. A controlled trial comparing foscarnet therapy with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N. Engl. J. Med. 325:551-555.
38. Sasadeusz, J., and S. L. Sacks. 1992. Systemic antivirals in herpes virus infections, p. 171-185. In S. M. Maddin and D. I. McLean (Ed.), Dermatologic clinics, vol. 11. W. B. Saunders Co., Philadelphia, Pa.
39. Sasadeusz, J. J., and S. L. Sacks. 1996. Spontaneous reactivation of thymidine kinase-deficient, acyclovir-resistant type 2 herpes simplex virus infection; masked heterogeneity or reversion? J. Infect. Dis. 174:476-482.
40. Shepp, D. H., B. A. Newton, P. S. Dandliker, N. Flournoy, and J. D. Meyers. 1985. Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients. Ann. Intern. Med. 102:783-785.
41. Siegal, F. P., C. Lopez, G. S. Hammer, A. E. Brown, S. J. Kornfeld, J. Gold, J. Hassett, S. Z. Hirschman, C. Cunningham-Rundles, B. R. Adelsberg, D. M. Parham, M. Siegal, S. Cunningham-Rundles, and D. Armstrong. 1981. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N. Engl. J. Med. 305: 1439-1444.
42. Streisinger, G., and J. Owen. 1985. Mechanisms of spontaneous and induced frameshift mutation in bacteriophage T4. Genetics 109:633-659.
43. Summers, W. P., M. Wagner, and W. C. Summers. 1975. Possible peptide chain termination mutants in thymidine kinase gene of a mammalian virus, herpes simplex virus. Proc. Natl. Acad. Sci. USA 72:4081-4084.
44. Talarico, C. L., W. C. Phelps, and K. K. Biron. 1993. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J. Virol. 67:1024-1033.
45. Tanaka, S., Y. Toh, and R. Mori. 1993. Molecular analysis of a neurovirulent herpes simplex virus type 2 strain with reduced thymidine kinase activity. Arch. Virol. 131:61-73.
46. Tenser, R. B., K. A. Hay, and W. A. Edris. 1989. Latency-associated transcript but not reactivatable virus is present in sensory ganglion neurons after inoculation of thymidine kinase-negative mutants of herpes simplex virus type 1. J. Virol. 63:2861-2865.
47. Wade, J. C., C. McLaren, and J. D. Meyers. 1983. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J. Infect. Dis. 148:1077-1082.
48. Wade, J. C., B. Newton, N. Flournoy, and J. D. Meyers. 1984. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann. Intern. Med. 100:823-828.
49. Whitley, R. J., M. Levin, N. Barton, B. J. Hershey, G. Davis, R. E. Keeney, J. Whelchel, A. G. Diethelm, P. Kartus, and S. J. Soong. 1984. Infections caused by herpes simplex virus in the immunocompromised host: natural history and topical acyclovir therapy. J. Infect. Dis. 150:323-329.
50. Wilson, J. B., A. Hayday, S. Courtneidge, and M. Fried. 1986. A frameshift at a mutational hot spot in the polyoma virus early region generates two new proteins that define T-antigen functional domains. Cell 44:477-487.